AI & Tech
Alzheimer’s Blood Tests Are Changing Decisions, Not Just Diagnoses
A randomised trial found that earlier disclosure of p-tau217 and neurofilament light results dramatically increased diagnostic certainty and changed management without increasing distress. Alzheimer’s blood biomarkers have crossed from accuracy into clinical utility.
Alzheimer’s Trials Still Measure Too Little, Too Late
AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved
Regulators Start Writing the Rules for AI-Driven Medicines
AI Pathology Moves From Demo to Workflow
FDA Puts AI Inside the Evidence Machine
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.